The agreement aims to improve medicine affordability while supporting U.S.-based manufacturing and pharmaceutical innovation. Johnson & Johnson healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs…
Gordian Bio Enters Research Partnership with Pfizer to Drive Obesity Target Discovery Gordian Bio, a biotechnology company pioneering large-scale in vivo functional genomics to unlock validated drug targets for chronic diseases, today announced a non-exclusive research collaboration with Pfizer to…
Collaboration focuses on advancing cell-specific siRNA therapies for cardiovascular disease treatment. Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small…
Analyses provide deeper insights into outcomes from the ALTAIR study presented at ASCO GI Natera, Inc., a global leader in cell-free DNA and precision medicine, announced that updated analyses from its ALTAIR clinical trial will be presented at the 2026…
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Bolstering Leadership in Rare Diseases, Driving Revenue Growth, and Enhancing Financial Outlook BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for…
Merck Strikes Deal with U.S. Government to Broaden Access to Medicines and Reduce Costs for Americans Merck, known as MSD outside of the United States and Canada, today announced a historic agreement with the Trump administration to ensure its prescription…
Alnylam to Invest $250M in Enzymatic Ligation Platform at U.S. Facility to Meet Global RNAi Demand Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing…
Zoetis Launches Proposed $1.75 Billion Offering of Convertible Senior Notes Zoetis Inc. today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering…
Sarepta Therapeutics Completes Refinancing of $291 Million in 1.25% Convertible Senior Notes Due 2027 Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a…
CVS Health Revises Financial Outlook, Showcases Business Strength, and Unveils Bold Strategy to Redefine Health Care at Investor Day CVS Health® will launch its strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique…
Lilly to Invest $6 Billion in Alabama Facility for Active Pharmaceutical Ingredient Production Eli Lilly and Company today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the…
Genmab Unveils New Phase 1b/2 EPCORE® CLL-1 Data Showcasing Epcoritamab’s Promise as Monotherapy and in Combination for Richter Transformation Patients Genmab A/S today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a…
